General Information
89 Bio NASH
A Randomized, Double Blind, Placebo Controlled, Multiple Ascending Dose Study to evaluate the Safety, Tolerability, and Pharmacokinetic Properties of 89Bio-100 Administered Subcutaneously in Subjects with Nonalcoholic Steatohepatitis (NASH) or with nonalcoholic fatty liver disease (NAFLD) and at increased risk of NASH
| Protocol | BIO89-100-002 |
|---|---|
| Identifier | 137-1346-BIO89 |
| UID | 8a64324b-5f78-41d0-bcf3-87ddb35ae7ed |
| Status | Done - Archived |
| Phase | Phase 1b |
| Category | NASH / Adult |
| Launch Year | 2020 |
| NCT Number | - |
| Created | 2020-01-15 13:26 |
| Last Updated | 2020-01-15 13:26 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | No | |
| Enrollment Open | 2020-02-11 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2020-02-03 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2021-03-04 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Casaclang, Cecilia | CCasaclang | No |
| Recruiter | - | No | |
| Coordinator | Gallardo, Michael | MGallardo | No |
| Regulatory | Perez, Myrna | MPerez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | 89Bio Ltd. |
|---|---|
| Division | 89Bio Ltd. |
| Team | 89Biob Ltd. |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | ProSciento, Inc. |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
